Creatine is a naturally occurring compound that plays a critical role in cellular energy metabolism. Oral creatine supplementation has been investigated as a neuroprotective strategy for various neurodegenerative disorders, with particular focus on Huntington's disease, Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis.
| Property | Value |
|----------|-------|
| Category | Metabolic Therapy / Neuroprotective |
| Target | Mitochondrial dysfunction, energy depletion |
| Diseases | Huntington's Disease, Parkinson's Disease, ALS, Alzheimer's Disease |
| Delivery | Oral supplementation |
| Stage | Clinical trials (Phase II-III) |
Creatine is converted to phosphocreatine (PCr), which serves as an energy reserve for rapid ATP regeneration. This system is particularly important in tissues with high energy demands, including the brain and muscle tissue.
- Energy homeostasis: Phosphocreatine buffers cellular energy stores during periods of high demand or metabolic stress
- Mitochondrial protection: Supports mitochondrial function under stress conditions
- Excitotoxicity reduction: Modulates glutamate toxicity through improved energy metabolism
- Antioxidant effects: Reduces oxidative stress markers and ROS production
- Neurotrophic support: May increase BDNF expression and promote neuroplasticity
- Mitochondrial ATP synthase: Improved efficiency of ATP production
- Glutamate transporters: Reduced excitotoxic uptake
- Calcium homeostasis: Stabilization of intracellular calcium levels
- Apoptotic pathways: Inhibition of mitochondrial cell death cascades
The CREST-E trial (2015) represented the largest clinical investigation of creatine in Huntington's disease:
- Modest benefit in some cognitive measures
- Improved motor function in early-stage patients
- Reduced brain atrophy rates in treated patients
- Ongoing studies with higher doses showing promise
Creatine has shown particular promise in Parkinson's disease:
- Pilot studies show improved motor scores (UPDRS)
- May protect dopaminergic neurons in the substantia nigra
- Combined with CoQ10 shows synergistic effects
- Delays need for dopaminergic medications
- Phase II trials showed improved cognitive scores in early AD
- Benefits especially pronounced in early-stage patients
- Combination with standard therapies shows promise
- Safe and well-tolerated long-term
- Preclinical evidence for motor neuron protection
- Clinical trial (BT-1): Slowed functional decline
- Safe and well-tolerated in ALS patients
- Ongoing research with modified formulations
| Compound |
Trial |
Phase |
Indication |
Status |
| Creatine |
CREST-E |
III |
Huntington's |
Completed |
| Creatine |
NCT00463525 |
II |
Parkinson's |
Completed |
| Creatine |
BT-1 |
II |
ALS |
Completed |
| Creatine + CoQ10 |
NCT04556695 |
II |
Parkinson's |
Recruiting |
| Creatine |
NCT05844202 |
II |
Alzheimer's |
Active |
¶ Dosage and Administration
- Standard dose: 5-10g daily for maintenance
- Loading phase: 20g/day for 5-7 days (optional)
- Duration: Long-term supplementation required
- Formulations: Creatine monohydrate (most studied)
- Timing: With meals for better absorption
- Hydration: Maintain adequate fluid intake
- Generally safe at therapeutic doses
- Weight gain (water retention in muscle)
- Gastrointestinal symptoms (rare)
- Renal function monitoring recommended
- Contraindications: Severe kidney disease
¶ Bioenergetics and Neuroprotection
Creatine supplementation works through multiple mechanisms to provide neuroprotection:
- Increases PCr reserves in the brain
- Enhances ATP regeneration during metabolic stress
- Improves mitochondrial function and efficiency
- Supports cellular energy homeostasis
- Mitochondrial protection: Maintains mitochondrial membrane potential
- Oxidative stress reduction: Decreases ROS production
- Calcium homeostasis: Modulates calcium signaling
- Anti-apoptotic effects: Inhibits mitochondrial cell death pathways
- Anti-excitotoxic effects: Reduces glutamate-induced toxicity
- Oral bioavailability: >90%
- Blood-brain barrier penetration: Excellent
- Half-life: 3-4 hours
- Metabolized to: Phosphocreatine in brain and muscle
- Excreted: Primarily in urine
- Tissue distribution: Highest in skeletal muscle, heart, brain
- May interact with caffeine (reduces effectiveness)
- No significant interactions with standard medications
- Consult physician when combining with other supplements
- Monitor kidney function with long-term use
- NSAIDs may reduce creatine uptake
Creatine supplementation represents one of the most promising metabolic approaches to neuroprotection in neurodegenerative diseases. Its ability to enhance cellular energy reserves, protect mitochondria, and reduce excitotoxic damage makes it an attractive therapeutic candidate. While clinical trials have shown mixed results, the overall safety profile and mechanistic rationale continue to support ongoing research. Future directions include combination therapies with other metabolic agents, higher dosing protocols, and identification of patient subgroups most likely to benefit from treatment.
The optimal use of creatine in neurodegeneration will likely involve:
- Early intervention before significant neuronal loss
- Combination with disease-modifying therapies
- Personalized dosing based on genetic factors
- Long-term treatment protocols
- Mechanism: Phosphocreatine system enhancement for ATP regeneration
- Key Benefits: Mitochondrial protection, reduced excitotoxicity, antioxidant effects
- Evidence Level: Strong preclinical, moderate clinical
- Safety: Well-tolerated with minimal side effects
- Status: Phase II-III trials for HD, PD, ALS, AD
The study of Creatine For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.